Jump to content

Acolbifene/prasterone

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 12:51, 21 December 2017. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Acolbifene/prasterone
Combination of
AcolbifeneSelective estrogen receptor modulator
PrasteroneAndrogen
Clinical data
Trade namesFemivia (tentative)
Other namesPrasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene
Routes of
administration		By mouth

Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women.[1] It is intended for use by mouth.[1] As of December 2017, it is in phase III clinical trials for this indication.[1]

See also

References

  1. ^ a b c http://adisinsight.springer.com/drugs/800043933



Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Acolbifene/prasterone&oldid=816455022"